FANTASTIC CLIMATE, EXCELLENT LOCATION
Ultra low cost production of high quality medical cannabis for the undersupplied domestic Israeli market along with rapid expansion into European markets.
As of August 2019, Israel is poised to become the third country behind Canada and Netherlands with an export framework. This opens the door for export into the massive European marketplace.
+46,000 patients in Israel with an estimated 90,000 anticipated by 2020. Underserved domestic market presents significant and immediate opportunity.
Germany is our entry point. With the export framework now in place, Isracann aims to become a premier supplier to the European market (pop. over 740 million, double USA and Canada). The EU medical market is estimated to be $64B USD by 2028.
Isracann Investor Relations